Premium
Intraputamenal infusion of glial cell line–derived neurotrophic factor in PD: A two‐year outcome study
Author(s) -
Patel Nikunj K.,
Bunnage Martin,
Plaha Puneet,
Svendsen Clive N.,
Heywood Peter,
Gill Steven S.
Publication year - 2005
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.20374
Subject(s) - glial cell line derived neurotrophic factor , neurotrophic factors , ciliary neurotrophic factor , outcome (game theory) , medicine , neuroscience , brain derived neurotrophic factor , neurotrophin , oncology , psychology , receptor , mathematics , mathematical economics
We have shown previously that intraparenchymal infusion of glial cell line–derived neurotrophic factor (GDNF) continuously into the posterior putamen in five Parkinson's disease patients is safe and may represent a new treatment option. Here, we report a continuation of this phase I study. After 2 years of continual GDNF infusion, there were no serious clinical side effects and no significant detrimental effects on cognition. Patients showed a 57% and 63% improvement in their off‐medication motor and activities of daily living subscores of the Unified Parkinson's Disease Rating Scale, respectively, and health‐related quality‐of‐life measures (Parkinson's Disease Questionnaire–39 and Short Form–36) showed general improvement over time. Ann Neurol 2005;57:298–302